Related references
Note: Only part of the references are listed.Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutierrez et al.
AIDS (2016)
Histone Deacetylase Inhibitor Romidepsin Inhibits De Novo HIV-1 Infections
Kasper L. Jonsson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients
Adam M. Spivak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir
Julia A. Sung et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat
Rikke Olesen et al.
JOURNAL OF VIROLOGY (2015)
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Kai Deng et al.
NATURE (2015)
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
Marta Martinez-Bonet et al.
SCIENTIFIC REPORTS (2015)
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Sogaard et al.
PLOS PATHOGENS (2015)
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
Sunil Sharma et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1
Grant R. Campbell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses
Jin-Gyo Oh et al.
MOLECULAR PHARMACOLOGY (2015)
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling
Guochun Jiang et al.
AIDS (2014)
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
Nancy M. Archin et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
Elizabeth R. Plimack et al.
ONCOLOGIST (2014)
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Julian H. Elliott et al.
PLOS PATHOGENS (2014)
Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
Richard Brad Jones et al.
PLOS PATHOGENS (2014)
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Datsen George Wei et al.
PLOS PATHOGENS (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
Marian Iwamoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo
Elizabeth J. Beans et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Reactivation of latent HIV by histone deacetylase inhibitors
Kotaro Shirakawa et al.
TRENDS IN MICROBIOLOGY (2013)
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+T Cells from Aviremic Patients
Celsa A. Spina et al.
PLOS PATHOGENS (2013)
Histone/protein deacetylases and T-cell immune responses
Tatiana Akimova et al.
BLOOD (2012)
Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
Sally Clive et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
Kuen-Tyng Lin et al.
CLINICAL CANCER RESEARCH (2012)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro
Brian A. DeChristopher et al.
NATURE CHEMISTRY (2012)
Bryostatin-1, a Naturally Occurring Antineoplastic Agent, Acts as a Toll-like Receptor 4 (TLR-4) Ligand and Induces Unique Cytokines and Chemokines in Dendritic Cells
Maria Eugenia Ariza et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2011)
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+T cells
Suha Saleh et al.
RETROVIROLOGY (2011)
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals
Ard van Sighem et al.
AIDS (2010)
Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma
Anthony P. Lam et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants
John C. Burnett et al.
JOURNAL OF VIROLOGY (2010)
Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
Rajeev Mehla et al.
PLOS ONE (2010)
Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid
Nancie M. Archin et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2009)
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant
Paul M. Barr et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Anna C. Pavlick et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Sukyung Woo et al.
CLINICAL CANCER RESEARCH (2009)
Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
Sophie Reuse et al.
PLOS ONE (2009)
Neuroprotective versus tumorigenic protein kinase C activators
T. J. Nelson et al.
TRENDS IN BIOCHEMICAL SCIENCES (2009)
Tailoring T-cell receptor signals by proximal negative feedback mechanisms
Oreste Acuto et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin
Hiroshi Uchida et al.
ENDOCRINOLOGY (2007)
Differential effect of bryostatin 1 and phorbol 12-myristate 13-acetate on HOP-92 cell proliferation is mediated by down-regulation of protein kinase Cδ
Sung Hee Choi et al.
CANCER RESEARCH (2006)
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-κB activation
Y Takada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor Ligation requires both PKCα and PKCθ
SA Trushin et al.
JOURNAL OF VIROLOGY (2005)
Prostratin antagonizes HIV latency by activating NF-κB
SA Williams et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue
A Biancotto et al.
JOURNAL OF VIROLOGY (2004)
Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
MR Betts et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Effects of prostratin on T-cell activation and human immunodeficiency virus latency
YD Korin et al.
JOURNAL OF VIROLOGY (2002)
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
JR Currier et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
Bryostatin-1 and IL-2 synergize to induce IFN-γ expression in human peripheral blood T cells:: Implications for cancer immunotherapy
RE Curiel et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
